Hidoc Dr | Medical Learning App for Doctors

Today's Updates

FDA Approves Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention Marco Meglio, Isabella Ciccone, MPH

Published Date: 13 Nov 2026

The FDA has approved asundexian, the first factor XIa inhibitor indicated to reduce recurrent stroke after a noncardioembolic ischemic stroke or high-risk TIA, based on phase 3 OCEANIC-STROKE data.

Consistent TAPS Use Associated With Underlying Tremor Improvement in Essential Tremor Isabella Ciccone, MPH

Published Date: 13 Nov 2026

An analysis of the PROSPECT trial reported that consistent use of transcutaneous afferent patterned stimulation was associated with improvement in underlying tremor severity in patients with essential tremor.

New CTE Prevalence Estimate Underscores Push for Diagnosis Living Patients Louie Pasculli, Rory Siegel, DO, Julian Bailes, MD

Published Date: 13 Nov 2026

A study of deceased former NFL players estimated that nearly 75% had CTE neuropathology, while a phase 3 trial is evaluating whether F-18 FNT-PET imaging could help identify disease-associated patterns in living patients.

Recapping MDS 2026: Biomarkers, Aging, and Prodromal Movement Disorders Marco Meglio, Odinachi Oguh, MD

Published Date: 13 Nov 2026

Odinachi Oguh, MD, movement disorder specialist at the Cleveland Clinic Lou Ruvo Center for Brain Health, shares clinical perspectives on biomarkers, aging, non-motor symptoms, and prodromal disease from the 2026 MDS Congress.

New York Forum Tackles Unmet Needs in Multiple Sclerosis Care Marco Meglio

Published Date: 13 Nov 2026

At a NeurologyLive Clinical Forum in New York, Mary Ann Piccone, MD, of Holy Name Medical Center, led a wide-ranging discussion among MS specialists on the limits of current high-efficacy therapies, the pipeline of emerging agents, and the gap between physician and patient treatment priorities.

Rezpegaldesleukin's Early Treg Signal in AD: Emma Guttman-Yassky, MD

Published Date: 13 Nov 2026

Rezpegaldesleukin's Early Treg Signal in AD: Emma Guttman-Yassky, MD

Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control

Published Date: 13 Nov 2026

Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control

Knowledge Hub

Oncology

Bispecific Antibody-Drug Conjugates for Targeted Elimination of Heterogeneous Tumor Cell Populations

A medical review of bispecific antibody-drug conjugates, including mechanisms, tumor heterogeneity, clinical applications, toxicities, emerging evidence, and future oncology practice.

Oncology

Coordinating Multidisciplinary Decision-Making for Cancer Recurrence Across Previously Treated Anatomical Sites

A multidisciplinary, evidence-based review of diagnosing and managing cancer recurrence in previously treated anatomical sites, including salvage therapy, reirradiation, systemic treatment, and guideline-informed coordination.

Oncology

Teaching Treatment Toxicity Recognition in Oncology: A Clinical and Evidence-Based Review

An evidence-based review of oncology treatment toxicity recognition, diagnosis, management, guideline recommendations, and educational strategies for healthcare professionals.

Oncology

Digital Cancer Survivorship Record Platforms: Clinical Utility, Governance, and Future Directions

A clinical review of digital cancer survivorship record platforms, including their uses, risks, governance, guideline alignment, and future potential.

Oncology

KOL Videos

Hidoc Dr| Hidoc- US| Hidoc - Doctor Netwoking Platform| Educational resource for HCPs

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

Your one-stop Solution for MEDICAL LEARNING & UPDATES

FDA Approves Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention Marco Meglio, Isabella Ciccone, MPH

Consistent TAPS Use Associated With Underlying Tremor Improvement in Essential Tremor Isabella Ciccone, MPH

New CTE Prevalence Estimate Underscores Push for Diagnosis Living Patients Louie Pasculli, Rory Siegel, DO, Julian Bailes, MD

Recapping MDS 2026: Biomarkers, Aging, and Prodromal Movement Disorders Marco Meglio, Odinachi Oguh, MD

New York Forum Tackles Unmet Needs in Multiple Sclerosis Care Marco Meglio

Rezpegaldesleukin's Early Treg Signal in AD: Emma Guttman-Yassky, MD

Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control

Knowledge Hub

Bispecific Antibody-Drug Conjugates for Targeted Elimination of Heterogeneous Tumor Cell Populations

Coordinating Multidisciplinary Decision-Making for Cancer Recurrence Across Previously Treated Anatomical Sites

Teaching Treatment Toxicity Recognition in Oncology: A Clinical and Evidence-Based Review

Digital Cancer Survivorship Record Platforms: Clinical Utility, Governance, and Future Directions

Forecasting Durable Cancer Control Through Tumor Clonal Succession Patterns After Local Therapy

Emerging Trends in Oncology and Precision Medicine

Emerging Trends in Oncology and Precision Medicine

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Page Views

Your one-stop Solution for MEDICAL LEARNING & UPDATES

FDA Approves Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention Marco Meglio, Isabella Ciccone, MPH

Consistent TAPS Use Associated With Underlying Tremor Improvement in Essential Tremor Isabella Ciccone, MPH

New CTE Prevalence Estimate Underscores Push for Diagnosis Living Patients Louie Pasculli, Rory Siegel, DO, Julian Bailes, MD

Recapping MDS 2026: Biomarkers, Aging, and Prodromal Movement Disorders Marco Meglio, Odinachi Oguh, MD

New York Forum Tackles Unmet Needs in Multiple Sclerosis Care Marco Meglio

Rezpegaldesleukin's Early Treg Signal in AD: Emma Guttman-Yassky, MD

Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control

Knowledge Hub

Bispecific Antibody-Drug Conjugates for Targeted Elimination of Heterogeneous Tumor Cell Populations

Coordinating Multidisciplinary Decision-Making for Cancer Recurrence Across Previously Treated Anatomical Sites

Teaching Treatment Toxicity Recognition in Oncology: A Clinical and Evidence-Based Review

Digital Cancer Survivorship Record Platforms: Clinical Utility, Governance, and Future Directions

Forecasting Durable Cancer Control Through Tumor Clonal Succession Patterns After Local Therapy

Emerging Trends in Oncology and Precision Medicine

Emerging Trends in Oncology and Precision Medicine

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Verification

Welcome to Hidoc Dr.

Page Views